Pharming Group

Pharming Group(PHAR)

LEIDEN, Netherlands
Biotechnology2 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Biologics

Pharming Group is a life sciences company focused on Biologics.

Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (1)

JOENJA
leniolisib
Peak
SMORAL · TABLET
PI3K-delta by blocking the active binding site of PI3K-delta. In cell-free isolated enzyme assays, leniolisib was selective for PI3K-delta over PI3K-alpha (28-fold), PI3K-beta (43-fold), and PI3K-gamma (257-fold), as well as the broader kinome. In cell-based assays, leniolisib reduced pAkt pathway activity and inhibited proliferation and activation of B and T cell subsets. Gain-of-function variants in the gene encoding the p110-delta catalytic subunit or loss of function variants in the gene encoding the p85-alpha regulatory subunit each cause hyperactivity of PI3K-delta. Leniolisib inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/Akt pathway, and to the dysregulation of B and T cells.
activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adultolder
2023
0

Pipeline & Clinical Trials

Phase 2
Clinical Trials (1)
NCT06990529Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation
Phase 2
Leniolisib
APDS
Phase 3
Clinical Trials (1)
NCT05693129Pediatric Patients Aged 1 to 6 Years With APDS
Phase 3
Leniolisib
APDS
Phase 3
Clinical Trials (1)
NCT05438407Pediatric Patients Aged 4 to 11 Years With APDS
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 1 approved product, 3 clinical trials
H-1B (2023): 2 approvals
Portfolio Health
Peak1 (100%)
1 total products

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub